TMPRSS2

Transmembrane protease serine 2 · O15393 · TMPRSS2 on Sugi Atlas →

10,748 patent compounds predicted against TMPRSS2, 6,875 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1648407	0.63	9/20
SCHEMBL2639194	0.74	8/20
SCHEMBL1648408	0.63	7/20
Guanisoquin (SCHEMBL2109074)	0.63	7/20
SCHEMBL3287685	0.50	6/20
Hydrochloric Acid (SCHEMBL2357315)	0.46	6/20
Hydrochloric Acid (SCHEMBL2357318)	0.46	6/20
Hydrochloric Acid (SCHEMBL2358557)	0.46	6/20
Hydrochloric Acid (SCHEMBL1789491)	0.44	6/20
Debrisoquin (SCHEMBL309184)	1.00	5/20
Debrisoquin (SCHEMBL122316)	0.84	5/20
Debrisoquin (SCHEMBL122317)	0.79	5/20
Guanisoquin (SCHEMBL121149)	0.55	4/20
SCHEMBL1188499	0.45	4/20
SCHEMBL1950276	0.49	3/20
SCHEMBL1263724	0.49	3/20
SCHEMBL308958	0.46	3/20
SCHEMBL1951535	0.46	3/20
SCHEMBL1188295	0.44	3/20
SCHEMBL1188339	0.44	3/20

Clinical trials — most relevant to TMPRSS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease	PHASE4	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19	PHASE2/PHASE3	UNKNOWN
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit	PHASE3	WITHDRAWN
Proxalutamide Treatment for COVID-19 Female Outpatients	PHASE3	WITHDRAWN
Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection	PHASE3	WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	PHASE2	COMPLETED
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer	PHASE2	COMPLETED
Nebulised BromAc in Healthy Volunteers	PHASE1	COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	EARLY_PHASE1	UNKNOWN
Hesperidin and Diosmin for Treatment of COVID-19	EARLY_PHASE1	UNKNOWN
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID	nan	RECRUITING
ACE2 Gender Differences in Stroke With COVID-19	nan	COMPLETED
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study	nan	WITHDRAWN
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.	nan	COMPLETED
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients	nan	UNKNOWN
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids	nan	WITHDRAWN
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity	nan	WITHDRAWN
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort	nan	UNKNOWN
Anti-Androgen Treatment for COVID-19	nan	COMPLETED
Association Between Periodontitis and Coronavirus Disease (COVID-19)	nan	COMPLETED
Periodontal Health in Post COVID-19 Patients	nan	UNKNOWN
Semen Analysis Changes in Covid-19 Positivepatients	nan	COMPLETED
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.	nan	UNKNOWN
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features	nan	UNKNOWN
Impact of the Genetic Polymorphism on COVID-19 in Egypt	nan	UNKNOWN
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)	nan	COMPLETED
Cardiac Injury in COVID-19: a Pathology Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TMPRSS2 binder may also engage these)

Protein	Name	Similarity
Q9JIQ8	—	0.999	Q9JIQ8 →
P49150	—	0.992	P49150 →
P29598	—	0.990	P29598 →
P98121	—	0.989	P98121 →
Q6ZMR5	—	0.988	Q6ZMR5 →
P19637	—	0.988	P19637 →
TMPRSS4	Transmembrane protease serine 4	0.988	landscape →
Q86T26	—	0.988	Q86T26 →
P57727	—	0.988	P57727 →
Q14C59	—	0.987	Q14C59 →
Q7RTY8	—	0.987	Q7RTY8 →
Q5R8J0	—	0.987	Q5R8J0 →
P11214	—	0.987	P11214 →
Q8BIK6	—	0.987	Q8BIK6 →
Q9UL52	—	0.986	Q9UL52 →
Q1JRP2	—	0.986	Q1JRP2 →
Q58L93	—	0.986	Q58L93 →
P26262	—	0.986	P26262 →
Q8MHY7	—	0.986	Q8MHY7 →
P04185	—	0.986	P04185 →
P86091	—	0.986	P86091 →
Q6ZWK6	—	0.985	Q6ZWK6 →
Q9WUW3	—	0.985	Q9WUW3 →
Q1L659	—	0.985	Q1L659 →
Q58L94	—	0.985	Q58L94 →
ST14	Suppressor of tumorigenicity 14 protein	0.985	landscape →
P56677	—	0.985	P56677 →
Q3UQ41	—	0.984	Q3UQ41 →
B4F6N6	—	0.984	B4F6N6 →
Q8BZ10	—	0.984	Q8BZ10 →